Sign for Notice Everyday    Sign Up| Sign In| Link|

Our Sponsors

    Receive Latest News

    Feedburner
    Share Us

    FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering

    View: 212

    Website https://www.complianceonline.com/fda-regenerative-medicine-stem-cell-treatments-tissue-engineering-s | Edit Freely

    Category

    Deadline: April 20, 2020 | Date: April 30, 2020-May 01, 2020

    Venue/Country: San Francisco, CA, U.S.A

    Updated: 2020-02-11 17:45:51 (GMT+9)

    Call For Papers - CFP

    This Seminar will provide an historical context for the use of stem cells in medicine, where the field has been and where it is going. It will also provide few examples of FDA approved use of stem cells in medicine and what is needed for the field to progress. Learn the fundamentals of stem cells and FDA’s regulatory approach for its use in medicine.

    Stem cells harness the power to differentiate into numerous cells upon stimulation. This has led to their wide exploration across all of medicine, including high risk diseases. Of course, significant scientific breakthroughs in the use of stem cells to prevent, diagnose, and treat numerous diseases has caused numerous start-up companies to form. Despite, such promise, the FDA has yet to approve stem cell therapies for a wide range of diseases, except cord blood-derived hematopoietic progenitor cells for certain indications. Attend this seminar to learn and apply the definitive ways to needed for the field to progress.


    Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
    Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.